Toward multi-targeted platinum and ruthenium drugs—a new paradigm in cancer drug treatment regimens?

RG Kenny, CJ Marmion - Chemical reviews, 2019 - ACS Publications
While medicinal inorganic chemistry has been practised for over 5000 years, it was not until
the late 1800s when Alfred Werner published his ground-breaking research on coordination …

What blocks more anticancer platinum complexes from experiment to clinic: Major problems and potential strategies from drug design perspectives

K Peng, BB Liang, W Liu, ZW Mao - Coordination Chemistry Reviews, 2021 - Elsevier
Encouraged by the worldwide success of cisplatin in the field of cancer chemotherapy,
intensive works have been conducted to explore more platinum coordination complexes as …

Disruption of Zinc Homeostasis by a Novel Platinum (IV)‐Terthiophene Complex for Antitumor Immunity

X Su, B Liu, WJ Wang, K Peng, BB Liang… - Angewandte …, 2023 - Wiley Online Library
Zinc homeostatic medicine is of great potential for cancer chemo‐immunotherapy; however,
there are few reports on antitumor compounds that can trigger Zn2+‐mediated immune …

Effects of intestinal microbial–elaborated butyrate on oncogenic signaling pathways

J Chen, KN Zhao, L Vitetta - Nutrients, 2019 - mdpi.com
The intestinal microbiota is well known to have multiple benefits on human health, including
cancer prevention and treatment. The effects are partially mediated by microbiota-produced …

Pt (IV) antitumor prodrugs: dogmas, paradigms, and realities

M Ravera, E Gabano, MJ McGlinchey, D Osella - Dalton Transactions, 2022 - pubs.rsc.org
Platinum (II)-based drugs are widely used for the treatment of solid tumors, especially in
combination protocols. Severe side effects and occurrence of resistance are the major …

Triple action Pt (iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance

E Petruzzella, R Sirota, I Solazzo, V Gandin… - Chemical …, 2018 - pubs.rsc.org
A series of triple action Pt (IV) prodrugs was designed to test the hypothesis that multi-action
compounds, where each bioactive moiety intervenes in several cellular processes, might be …

Platinum (IV) and platinum (II) anticancer complexes with biologically active releasable ligands

P Štarha, R Křikavová - Coordination Chemistry Reviews, 2024 - Elsevier
The concept of multi-action octahedral platinum (IV) complexes is based on the rational
derivatization of anticancer square-planar platinum (II) compounds (eg, cisplatin or …

Current developments in Pt (IV) prodrugs conjugated with bioactive ligands

X Li, Y Liu, H Tian - Bioinorganic chemistry and applications, 2018 - Wiley Online Library
To overcome the side effects of and resistance to cisplatin, a variety of Pt (IV) prodrugs were
designed and synthesized via different modifications including combination with lipid chains …

A view on multi-action Pt (IV) antitumor prodrugs

M Ravera, E Gabano, MJ McGlinchey, D Osella - Inorganica Chimica Acta, 2019 - Elsevier
Platinum (IV) complexes are particularly appealing as prodrugs since their relative inertness,
and consequent low toxicity outside the cell is matched by their high activity inside the tumor …

In vitro evaluations of biomolecular interactions, antioxidant and anticancer activities of Nickel (II) and Copper (II) complexes with 1: 2 coordination of anthracenyl …

KS Neethu, S Sivaselvam, M Theetharappan… - Inorganica Chimica …, 2021 - Elsevier
A set of nickel (II) and copper (II) complexes incorporated anthracenyl hydrazone ligands
were synthesized and characterized with the help of various spectroscopic techniques …